ABN Amro Investment Solutions Makes New $1.15 Million Investment in Bristol Myers Squibb Company $BMY

ABN Amro Investment Solutions purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 24,821 shares of the biopharmaceutical company’s stock, valued at approximately $1,149,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wellington Management Group LLP boosted its position in Bristol Myers Squibb by 297.0% during the 1st quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company’s stock worth $1,447,198,000 after acquiring an additional 17,750,938 shares during the last quarter. GQG Partners LLC lifted its position in shares of Bristol Myers Squibb by 22,647.6% in the first quarter. GQG Partners LLC now owns 12,023,454 shares of the biopharmaceutical company’s stock worth $733,310,000 after purchasing an additional 11,970,598 shares in the last quarter. Nuveen LLC acquired a new position in Bristol Myers Squibb during the first quarter worth $624,369,000. Kingstone Capital Partners Texas LLC bought a new position in Bristol Myers Squibb in the second quarter valued at $98,898,000. Finally, Goldman Sachs Group Inc. increased its stake in Bristol Myers Squibb by 17.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,051,319 shares of the biopharmaceutical company’s stock valued at $856,990,000 after buying an additional 2,117,249 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.09% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of recent research reports. Daiwa Capital Markets downgraded Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price on the stock. in a research report on Tuesday, August 5th. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Finally, Scotiabank initiated coverage on shares of Bristol Myers Squibb in a research note on Thursday. They issued a “sector perform” rating and a $45.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $54.58.

Bristol Myers Squibb Stock Down 4.0%

Shares of BMY opened at $46.67 on Friday. The firm’s 50-day simple moving average is $45.34 and its 200 day simple moving average is $46.70. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The firm has a market cap of $95.00 billion, a P/E ratio of 18.82, a price-to-earnings-growth ratio of 2.23 and a beta of 0.33. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd were given a dividend of $0.62 per share. The ex-dividend date was Friday, October 3rd. This represents a $2.48 annualized dividend and a yield of 5.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 83.78%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.